- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Vital Images appoints new VP
Philip I. Smith has been named vice president of corporate development at Vital Images. The position was created to drive growth through the development of strategic relationships that will broaden sales and marketing channels and integrate new
Philip I. Smith has been named vice president of corporate development at Vital Images. The position was created to drive growth through the development of strategic relationships that will broaden sales and marketing channels and integrate new technologies. Smith will also be charged with pursuing any merger and acquisition efforts undertaken by the company.
Smith is an 11-year veteran of corporate finance, strategic planning, and market development positions in medical technology companies. Prior to joining Vital Images, he worked for two early-stage medical technology companies: as president and CEO of Thermonix in Minneapolis, and as vice president of marketing and business development for Image-Guided Neurologics in Melbourne, FL. Smith was previously an investment banker in the medical technology group of the investment firm US Bancorp Piper Jaffray and held senior sales positions at GE Medical Systems.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
